ホーム > 市場調査レポート > 医薬品 > 製薬企業関連 > バイオテクノロジー企業および専門製薬会社におけるマーケティングおよび販売ベストプラクティス
カテゴリ
医薬品 (4955)
OTC (153)
がん (943)
ドラッグデリバリー (185)
ワクチン (182)
感染症 (351)
規制環境 (130)
後発医薬品 (134)
骨疾患 (37)
処方薬 (157)
神経疾患 (174)
精神疾患 (88)
製薬企業関連 (531)
創薬 (1523)
糖尿病 (192)
動物用医薬 (17)
肥満症 (44)
市場調査レポート

バイオテクノロジー企業および専門製薬会社におけるマーケティングおよび販売ベストプラクティス

Marketing and Sales Organization Best Practices for Biotech and Specialized Pharma

発行 Decision Resources, Inc.
出版日 2006年06月 商品コード 41954
ページ情報 英文 18 Pages
価格
こちらの商品の販売は終了いたしました。

当商品の販売は、2011年12月21日を持ちまして終了しました。

原文目次

Abstract

In this report, we present the results of a study we performed in Europe in 2005 to identify best practices in marketing and sales strategies among high-performing and profitably growing biotech and midsize specialized pharmaceutical companies. The survey stressed the importance of a company's commercialization model, its organizational structure, and its allocation of marketing and sales functions during different stages of business development and at different corporate levels (i.e., globally, regionally across Europe, and at the local country level). We surveyed 18 high-performing companies with annual revenues of more than $100 million and gained valuable insight into the optimal methods of pharmaceutical and biotech commercial organization in Europe.

Table of Contents

  • High-Performing Biotech and Specialized Pharmaceutical Companies
  • Marketing and Sales Organization Survey
  • Operational Models for Marketing and Sales
  • Criteria for Choosing a Partner
  • Establishing Country Affiliates
  • Organizational Structure
  • Retained European Headquarters Model
  • Reduced European Headquarters Model
  • Best Practices in Allocating Roles and Responsibilities when Expanding into EU-5 Markets
  • Portfolio and Marketing Strategies Need Global Control
  • Clinical Trials, Health Economics, and KOL Management
  • Synergistic Benefits from Regulatory Affairs and Marketing and Sales Support
  • Country-Specific Requirements at the Local Level
  • Common Mistakes when Expanding into EU-5 Markets
  • Path for Evaluating an Optimal Organization
  • Figure 1 Biotech and Specialized Pharma Companies Taking Part in the Survey
  • Figure 2 Organization Choices for Marketing and Sales
  • Figure 3 Predominant Operational Marketing and Sales Models Used by Biotech and Midsize Specialized Pharma Companies in Europe
  • Figure 4 Drivers Behind the Choice of Operational Models for Marketing and Sales in the European Union
  • Figure 5 Two Models of European Union Headquarters Development Over Time
  • Figure 6 Perceived Best Practices for Allocation of Marketing and Sales Functions
  • Figure 7 Bottom-Up Evaluation Process for an Optimal Organizational Development Plan
  • Table 1 Preferences in Choosing the Size of an External Sales and Marketing Partner
  • Table 2 Profile of the "Ideal" European General Manager
  • Table 3 Most Common Mistakes when Expanding into the European Union-5
Back to Top